Last updated: April 24, 2026
Which entities supply KENALOG-40 (triamcinolone acetonide) for the market?
KENALOG-40 is a branded corticosteroid product containing triamcinolone acetonide (TAA) 40 mg/mL (intramuscular suspension). Public-facing supply channels typically route through the brand’s marketing authorization holder and its distribution network, then into wholesalers and institutions. However, supplier identification down to the API manufacturer and finished-dose contract manufacturer is not consistently published in open sources.
What is reliably identifiable in open sources:
- Sanofi-Aventis U.S. LLC is the U.S. marketing authorization holder for KENALOG-40-related label materials in the United States (brand owner for supply and distribution channels).
- Distribution occurs through standard pharmaceutical supply chains (wholesalers, hospital distribution, and group purchasing organizations), but these do not map cleanly to named API or CMO suppliers in public documentation.
Which suppliers are confirmed for finished product distribution?
In the U.S., KENALOG-40 supply is tied to the brand’s label holder and its downstream distribution partners. Confirmed entity:
| Category |
Supplier / Entity |
Role in KENALOG-40 supply |
| Marketing authorization holder (U.S. label) |
Sanofi-Aventis U.S. LLC |
Controls U.S. brand supply chain and distribution network under the product label |
Source: KENALOG-40 label information identifying Sanofi-Aventis U.S. LLC as the U.S. label holder (see cited labeling source).
Who supplies the active ingredient (triamcinolone acetonide)?
API suppliers for triamcinolone acetonide are not consistently disclosed in open regulatory label text. API sourcing is often governed through:
- DMF filings (not fully searchable to provide named suppliers across all jurisdictions)
- confidential material transfer and sourcing agreements
- supplier lists inside CMO/OSP documentation that is not publicly posted
As a result, a definitive, supplier-level list for triamcinolone acetonide API for KENALOG-40 cannot be produced from publicly indexed sources with the level of specificity required for decision-grade sourcing.
What procurement-relevant supplier types should buyers screen for KENALOG-40?
While the API and CMO names cannot be fully confirmed from open sources, KENALOG-40 purchasing commonly uses these procurement categories:
- Brand owner and authorized distributors (U.S.): sourced via Sanofi’s distribution network
- Wholesalers: carry branded injectable products for retail pharmacy and institutional channels
- Institutional group purchasing: contract pricing and availability channels, typically without disclosing API/CMO identity
- Generic interchange: substitutes may indicate different manufacturers even when the API is the same
How do you identify substitute supply risk if API sourcing is opaque?
For KENALOG-40, substitution risk is driven more by finished-dose manufacturing site changes and market availability than by API identity alone. Buyers should track:
- NDC level manufacturer/labeler changes (when they occur)
- batch-specific labeling and packaging changes
- distributor backorder patterns
- regional shortages of corticosteroid injectables
Market and regulator scope: why supplier names are hard to pin down publicly
Open label text typically names:
- the label holder,
- prescribing information,
- and controlled distribution points,
but it rarely names:
- the API manufacturer,
- or the finished-dose CMO.
For decision-grade supplier mapping, these are usually found in:
- DMF cover sheets,
- full prescribing package inserts plus manufacturing section details where available,
- or publicly posted inspection and consent decree records tied to a specific manufacturing site.
Those documents are not uniformly accessible in open form for a complete KENALOG-40 supplier list across jurisdictions.
Key Takeaways
- Sanofi-Aventis U.S. LLC is the confirmed U.S. label holder for KENALOG-40 supply and distribution control.
- Open public sources do not provide a complete, decision-ready list of API or contract finished-dose manufacturers for KENALOG-40.
- For procurement and substitution-risk monitoring, focus on NDC/labeler, batch/package changes, and availability signals in wholesalers and institutions.
FAQs
1) Who is the U.S. label holder for KENALOG-40?
Sanofi-Aventis U.S. LLC is identified as the U.S. label holder.
2) Can I name the API supplier for triamcinolone acetonide used in KENALOG-40 from public sources?
A complete, confirmed API supplier list cannot be derived from publicly indexed label/regulatory text at the granularity needed for procurement-grade sourcing.
3) Who manufactures the finished KENALOG-40 suspension under contract?
Public sources do not consistently disclose the finished-dose CMO for KENALOG-40 in a way that supports a definitive supplier list.
4) What supplier entities can be tracked for purchasing reliability?
Track the brand’s authorized distribution and the wholesaler/institutional channel that carries the specific NDC and batch.
5) How do shortages typically manifest for KENALOG-40?
They more often show up as availability disruptions by channel and NDC, rather than as publicly disclosed changes in API or CMO identity.
References (APA)
[1] Sanofi-Aventis U.S. LLC. (n.d.). KENALOG-40 (triamcinolone acetonide) injection, suspension, label information. Drug label / prescribing information.
